Citations (82)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
Pedro Santos-Moreno, Guillermo Sánchez-Vanegas, Angélica Monterrosa-Blanco, Gabriel-Santiago Rodríguez-Vargas, Manuel Rivero, Pedro Rodriguez, Omar-Javier Calixto, Adriana Rojas-Villarraga & Carlos Alberto Castro. (2022) Adherence to Subcutaneous Anti-Tumour Necrosis Factor Treatment in a Cohort of Patients with Rheumatoid Arthritis Before and After the Implementation of a Comprehensive Care Model. Biologics: Targets and Therapy 16, pages 199-209.
Read now
Read now
Niamh Kearney & Kevin McKenna. (2022) Real world use of biologic drug levels and anti-drug antibodies in patients with psoriasis – does therapeutic drug monitoring have a place in routine clinical practice?. Journal of Dermatological Treatment 33:3, pages 1676-1681.
Read now
Read now
Neil J. Korman, William Malatestinic, Orin M. Goldblum, Mwangi J. Murage, Lisa Renda, Chen-Yen Lin, James Lucas, Chloe Middleton & Steven Lobosco. (2022) Assessment of the benefit of achieving complete versus almost complete skin clearance in psoriasis: a patient’s perspective. Journal of Dermatological Treatment 33:2, pages 733-739.
Read now
Read now
Mohammed A Omair, Fatima Al Suwayeh, Alanoud Almashaan, Eman Alqurtas, Mohammed K Bedaiwi, Ibrahim Almaghlouth, Abdulaziz Alkahalaf & Haya M Almalaq. (2021) Cross-Cultural Validation of the 5-Item Compliance Questionnaire for Rheumatology to the Arabic Language in Patients with Rheumatoid Arthritis. Patient Preference and Adherence 15, pages 1461-1467.
Read now
Read now
Peter C Taylor, Codrina Ancuta, Orsolya Nagy, María C de la Vega, Andrey Gordeev, Radka Janková, Umut Kalyoncu, Ivan Lagunes-Galindo, Jadranka Morović-Vergles, Mariana Peixoto G U e Silva de Souza, Bernadette Rojkovich, Prodromos Sidiropoulos & Atsushi Kawakami. (2021) Treatment Satisfaction, Patient Preferences, and the Impact of Suboptimal Disease Control in a Large International Rheumatoid Arthritis Cohort: SENSE Study. Patient Preference and Adherence 15, pages 359-373.
Read now
Read now
ME D’Amico, E Silvagni, G Carrara, A Zanetti, M Govoni, CA Scirè & A Bortoluzzi. (2021) Role of comorbidities on therapeutic persistence of biological agents in rheumatoid arthritis: results from the RECord-linkage On Rheumatic Disease study on administrative healthcare databases. Scandinavian Journal of Rheumatology 50:5, pages 333-342.
Read now
Read now
Kağan Cingöz, Kamer Gündüz & Işıl İnanır. (2021) Patients’ knowledge about psoriasis and comorbidities; their participation in treatment decisions. Journal of Dermatological Treatment 32:2, pages 212-214.
Read now
Read now
Mwangi J. Murage, Adrienne M. Gilligan, Oth Tran, Orin Goldblum, Russel Burge, Chen-Yen Lin & Abrar Qureshi. (2021) Ixekizumab treatment patterns and healthcare utilization and costs for patients with psoriasis. Journal of Dermatological Treatment 32:1, pages 56-63.
Read now
Read now
Valentina Perrone, Elisa Giacomini, Diego Sangiorgi, Margherita Andretta, Anna Michela Menti, Mariantonietta Naclerio, Daniela Ritrovato & Luca Degli Esposti. (2020) Treatment Pattern Analysis and Health-care Resource Consumption on Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Biological Drugs in a Northern Italian Region. Therapeutics and Clinical Risk Management 16, pages 509-521.
Read now
Read now
Luca Degli Esposti, Stefano Buda, Carmela Nappi, Daniela Paoli & Valentina Perrone. (2020) Implications of COVID-19 Infection on Medication Adherence with Chronic Therapies in Italy: A Proposed Observational Investigation by the Fail-to-Refill Project. Risk Management and Healthcare Policy 13, pages 3179-3185.
Read now
Read now
Andrew Blauvelt, Nianwen Shi, Russel Burge, William N Malatestinic, Chen-Yen Lin, Carolyn R Lew, Nicole M Zimmerman, Orin M Goldblum, Baojin Zhu & Mwangi J Murage. (2020) Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab. Patient Preference and Adherence 14, pages 517-527.
Read now
Read now
Donghoon Shin, Younsoo Kim, Ahra Go & Maria Velinova. (2020) Comparison of the Pharmacokinetics, Safety, and Tolerability of the Autoinjector (AI) and Pre-Filled Syringe (PFS) of SB4 in Healthy Subjects. Drug Design, Development and Therapy 14, pages 43-50.
Read now
Read now
Jashin J. Wu, Corey Pelletier, Brian Ung & Marc Tian. (2020) Treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriatic arthritis: results from a US claims analysis. Current Medical Research and Opinion 36:1, pages 169-176.
Read now
Read now
Thierry Conrozier, Jean-Luc Renevier, Jean-Marc Parisaux & Jean-Charles Balblanc. (2019) Predictive factors of adherence to an association of glucosamine sulfate, copper, and ginger extracts in patients with symptomatic osteoarthritis: a prospective open-label French noninterventional study (the PREDOA study). Patient Preference and Adherence 13, pages 915-921.
Read now
Read now
Articles from other publishers (68)
Jack A. Cummins, Guohai Zhou & Vinod E. Nambudiri. (2023) Natural Language Processing for Large-Scale Analysis of Eczema and Psoriasis Social Media Comments. JID Innovations 3:5, pages 100210.
Crossref
Crossref
Ana Liani Beisl Oliveira, Elisangela Costa Lima, Mônica Campos & Vera Lucia Luiza. (2023) Drugs for rheumatoid arthritis provided by the Unified Health System in 2019 in Brazil: a cohort study. Ciência & Saúde Coletiva 28:5, pages 1443-1456.
Crossref
Crossref
Ana Liani Beisl Oliveira, Elisangela Costa Lima, Mônica Campos & Vera Lucia Luiza. (2023) Medicamentos para artrite reumatoide fornecidos pelo Sistema Único de Saúde em 2019 no Brasil: estudo de coorte. Ciência & Saúde Coletiva 28:5, pages 1443-1456.
Crossref
Crossref
A. Mark Fendrick, Philip Mease, Matthew Davis, Pankaj Patel, Wes Matthias, Dominic Nunag & Manish Mittal. (2023) Continuity of Care Within a Single Patient Support Program for Patients with Rheumatoid Arthritis Prescribed Second or Later Line Advanced Therapy. Advances in Therapy 40:3, pages 990-1004.
Crossref
Crossref
Christos Ermeidis, Theodoros Dimitroulas, Chryssa Pourzitaki, Paraskevi V. Voulgari & Dimitrios Kouvelas. (2023) Perceived treatment satisfaction in patients with systemic rheumatic diseases treated with biologic therapies: results of a self-reported survey. Rheumatology International 43:6, pages 1151-1159.
Crossref
Crossref
Laure Gossec, Stefan Siebert, Paul Bergmans, Kurt de Vlam, Elisa Gremese, Beatriz Joven-Ibáñez, Tatiana V Korotaeva, Frederic Lavie, Wim Noël, Michael T Nurmohamed, Petros P Sfikakis, Mohamed Sharaf, Elke Theander & Josef S Smolen. (2022) Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study. Annals of the Rheumatic Diseases, pages annrheumdis-2022-222879.
Crossref
Crossref
M. J. H. Voshaar, B. J. F. van den Bemt, M. A. F. J. van de Laar, A. M. van Dulmen & J. E. Vriezekolk. (2022) Healthcare professionals’ perceptions on barriers and facilitators to DMARD use in rheumatoid arthritis. BMC Health Services Research 22:1.
Crossref
Crossref
Anne-Laure Yailian, Charline Estublier, Aurélie Fontana, Emmanuelle Vignot, Cyrille Confavreux, Roland Chapurlat, Humbert de Fréminville & Audrey Janoly-Dumenil. (2022) Practices among General Practitioners in Rheumatoid Arthritis (GEPRA-I): results of a region-wide online survey. BMC Primary Care 23:1.
Crossref
Crossref
Georg Gross, Christian Lull, Jan von Ahnen, Victor Olsavszky, Johannes Knitza, Astrid Schmieder & Jan Leipe. (2022) German Mobile Apps for Patients with Psoriatic Arthritis: Systematic App Search and Content Analysis. Health Policy and Technology 11:4, pages 100697.
Crossref
Crossref
Bart P H Pouls, Charlotte L Bekker, Fatma Gundogan, Renske CF Hebing, Hein AW van Onzenoort, Liesbeth I van de Ven, Harald E Vonkeman, Rob Tieben, Johanna E Vriezekolk, Sandra van Dulmen & Bart Van den Bemt. (2022) Gaming for Adherence to Medication using Ehealth in Rheumatoid arthritis (GAMER) study: a randomised controlled trial. RMD Open 8:2, pages e002616.
Crossref
Crossref
Michael J. Woodbury, Jeffrey M. Cohen, Joseph F. Merola & Lourdes M. Perez-Chada. (2022) Leveraging behavioral economics to promote treatment adherence: A primer for the practicing dermatologist. Journal of the American Academy of Dermatology 87:5, pages 1075-1080.
Crossref
Crossref
Marko Krstic, Jean-Christophe Devaud, Farshid Sadeghipour & Joachim Marti. (2022) Current Expertise, Opinions, and Attitude toward TNF-⍺ Antagonist Biosimilars among Physicians: A Self-Administered Online Survey in Western Switzerland. Healthcare 10:11, pages 2152.
Crossref
Crossref
Amanda M. Kibbons, Ryan Moore, Leena Choi, Megan Peter & Autumn D. Zuckerman. (2022) Individual and Community-Level Characteristics and Adherence to Specialty Medications. Journal of Pharmacy Practice, pages 089719002211319.
Crossref
Crossref
Rotem Semo-Oz, Linda Wagner-Weiner, Cuoghi Edens, Carolyn Zic, Karen One, Nadine Saad & Melissa Tesher. (2022) Adherence to medication by adolescents and young adults with childhood-onset systemic lupus erythematosus. Lupus 31:12, pages 1508-1515.
Crossref
Crossref
Sanjana Tarannum, Ying-Ying Leung, Sindhu R. Johnson, Jessica Widdifield, Vibeke Strand, Paula Rochon & Lihi Eder. (2022) Sex- and gender-related differences in psoriatic arthritis. Nature Reviews Rheumatology 18:9, pages 513-526.
Crossref
Crossref
P. O. Postnikova, P. S. Kovalenko, I. S. Dydykina, A. V. Aboleshina & A. M. Lila. (2022) Analysis of adherence to treatment in patients with rheumatoid arthritis. Modern Rheumatology Journal 16:4, pages 40-45.
Crossref
Crossref
Irazú Contreras-Yáñez, Guillermo Arturo Guaracha-Basáñez, Maximiliano Cuevas-Montoya, José de Jesús Hernández-Bautista & Virginia Pascual-Ramos. (2022) Early persistence on therapy impacts drug-free remission: a case-control study in a cohort of Hispanic patients with recent-onset rheumatoid arthritis. Arthritis Research & Therapy 24:1.
Crossref
Crossref
Olav Gjønnes Tvedten, Anne Croker, Marina Lawrence, Katrina Williams, Narelle Perry & Jim Croker. (2022) Personalised written consultation summaries for patients: An ‘up-close, in-depth, inside-out’ exploration of a rheumatologist's patient-centred strategy. Patient Education and Counseling 105:7, pages 2362-2370.
Crossref
Crossref
Miranda Z. Kozlicki, Brandon Markley, Nisha B. Shah, Josh DeClercq, Leena Choi & Autumn D. Zuckerman. (2022) A cross-sectional analysis of persistence to disease-modifying therapies in treatment naïve and experienced patients with relapsing multiple sclerosis at a health-system specialty pharmacy. Multiple Sclerosis and Related Disorders 63, pages 103860.
Crossref
Crossref
Laure Gossec, Stefan Siebert, Paul Bergmans, Kurt de Vlam, Elisa Gremese, Beatríz Joven-Ibáñez, Tatiana V Korotaeva, Frederic Lavie, Wim Noël, Michael T Nurmohamed, Petros P Sfikakis, Elke Theander & Josef S Smolen. (2022) Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study. Annals of the Rheumatic Diseases 81:6, pages 823-830.
Crossref
Crossref
Philip J. Mease, Pamela Young, David Gruben, Lara Fallon, Rebecca Germino & Arthur Kavanaugh. (2022) Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims Database. Advances in Therapy 39:6, pages 2932-2945.
Crossref
Crossref
Christian Lull, Jan Alwin von Ahnen, Georg Gross, Victor Olsavszky, Johannes Knitza, Jan Leipe & Astrid Schmieder. (2022) German Mobile Apps for Patients With Psoriasis: Systematic Search and Evaluation. JMIR mHealth and uHealth 10:5, pages e34017.
Crossref
Crossref
Tejal Patel, Jessica Ivo, Teresa Pitre, Sadaf Faisal, Kristen Antunes & Kasumi Oda. (2022) An In-Home Medication Dispensing System to Support Medication Adherence for Patients With Chronic Conditions in the Community Setting: Prospective Observational Pilot Study. JMIR Formative Research 6:5, pages e34906.
Crossref
Crossref
Ronaldo José Faria, Francisca Janiclecia Rezende Cordeiro, Jéssica Barreto Ribeiro dos Santos, Juliana Alvares-Teodoro, Augusto Afonso Guerra Júnior, Francisco de Assis Acurcio & Michael Ruberson Ribeiro da Silva. (2022) Conventional Synthetic Disease-Modifying Anti-rheumatic Drugs for Psoriatic Arthritis: Findings and Implications From a Patient Centered Longitudinal Study in Brazil. Frontiers in Pharmacology 13.
Crossref
Crossref
Eugenia Piragine, Davide Petri, Alma Martelli, Agata Janowska, Valentina Dini, Marco Romanelli, Vincenzo Calderone & Ersilia Lucenteforte. (2022) Adherence and Persistence to Biological Drugs for Psoriasis: Systematic Review with Meta-Analysis. Journal of Clinical Medicine 11:6, pages 1506.
Crossref
Crossref
Patricia SchepmanSheena ThakkarRebecca Robinson, Craig Beck, Deepa Malhotra, Birol Emir & Ryan Hansen. (2022) A Retrospective Claims-Based Study Evaluating Clinical and Economic Burden Among Patients With Moderate to Severe Osteoarthritis Pain in the United States. Journal of Health Economics and Outcomes Research 9:1, pages 58-67.
Crossref
Crossref
Andrew Blauvelt, Russel Burge, Gaia Gallo, Bridget Charbonneau, William Malatestinic, Baojin Zhu, Fangyu Wan & Benjamin Lockshin. (2022) A Retrospective Cohort Analysis of Treatment Patterns Over 1 Year in Patients with Psoriasis Treated with Ixekizumab or Guselkumab. Dermatology and Therapy 12:3, pages 701-714.
Crossref
Crossref
Bart PH Pouls, Charlotte L Bekker, Sandra van Dulmen, Johanna E Vriezekolk & Bart JF van den Bemt. (2022) A Serious Puzzle Game to Enhance Adherence to Antirheumatic Drugs in Patients With Rheumatoid Arthritis: Systematic Development Using Intervention Mapping. JMIR Serious Games 10:1, pages e31570.
Crossref
Crossref
Sahar Dadkhahfar, Laya Ohadi, Yasaman Rahimi, Reza M. Robati, Marjan Shekarabi, Omid Zargari & Mohammad Shahidi‐Dadras. (2021) Patients' perception, and adherence to treatment with biosimilar adalimumab in psoriasis. Dermatologic Therapy 35:2.
Crossref
Crossref
György Nagy, Nadia M T Roodenrijs, Paco M J Welsing, Melinda Kedves, Attila Hamar, Marlies C van der Goes, Alison Kent, Margot Bakkers, Polina Pchelnikova, Etienne Blaas, Ladislav Senolt, Zoltan Szekanecz, Ernest H Choy, Maxime Dougados, Johannes WG Jacobs, Rinie Geenen, Johannes WJ Bijlsma, Angela Zink, Daniel Aletaha, Leonard Schoneveld, Piet van Riel, Sophie Dumas, Yeliz Prior, Elena Nikiphorou, Gianfranco Ferraccioli, Georg Schett, Kimme L Hyrich, Ulf Mueller-Ladner, Maya H Buch, Iain B McInnes, Désirée van der Heijde & Jacob M van Laar. (2022) EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Annals of the Rheumatic Diseases 81:1, pages 20-33.
Crossref
Crossref
Ilteris Oguz Topal, Asude Kara Polat, İlkin Zindancı, İlknur Kıvanç Altunay, Tuğba Özkök Akbulut, Eylem Emel Arıkan, Filiz Topaloğlu Demir, Onur Sivaz & Ayşe Serap Karadağ. (2021) Adherence to systemic therapy in patients with psoriasis during the COVID‐19 pandemic: A multicenter study. Journal of Cosmetic Dermatology 21:1, pages 39-47.
Crossref
Crossref
Qisi Sun, Patrick O. Perche, Varun K. Ranpariya & Steven R. Feldman. 2022. Biologic Therapy for Psoriasis. Biologic Therapy for Psoriasis
131
141
.
Mark G. Lebwohl. (2021) Comment on “Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis”. Journal of the American Academy of Dermatology 85:6, pages e377.
Crossref
Crossref
Mwangi J. Murage, Nicole Princic, Julie Park, William Malatestinic, Baojin Zhu, Bilal Atiya, Scott A. Kern, Keri B. Stenger, Aubrey Trevelin Sprabery & Alexis Ogdie. (2021) Real‐World Treatment Patterns and Healthcare Costs in Patients with Psoriatic Arthritis Treated with Ixekizumab: A Retrospective Study. ACR Open Rheumatology 3:12, pages 879-887.
Crossref
Crossref
Joeseph Nenow, Esthe Balogh & Steven Feldman. (2021) Emerging Treatment Regimens in Psoriasis: Are There Advantages Over Current Biologic Therapies?. EMJ Dermatology, pages 106-121.
Crossref
Crossref
Nadia M T Roodenrijs, Marlies C van der Goes, Paco M J Welsing, Eline P C van Oorschot, Elena Nikiphorou, Nienke C Nijhof, Janneke Tekstra, Floris P J G Lafeber, Johannes W G Jacobs, Jacob M van Laar & Rinie Geenen. (2021) Non-adherence in difficult-to-treat rheumatoid arthritis from the perspectives of patients and rheumatologists: a concept mapping study. Rheumatology 60:11, pages 5105-5116.
Crossref
Crossref
Armaan Guraya, Uros Rakita, Caroline L. Porter & Steven R. Feldman. (2021) A narrative review of systematic reviews on adherence to psoriasis treatments. Dermatological Reviews 2:5, pages 251-261.
Crossref
Crossref
Charlotte L. Bekker, Sacha Bossina, Mary A. de Vera, Susan J. Bartlett, Maarten de Wit, Lyn March, Beverley Shea, Vicki Evans, Dawn Richards, Allison Tong, Peter Tugwell, Kathleen Tymms, Marieke Scholte-Voshaar, Ayano Kelly & Bart J.F. van den Bemt. (2021) Patient Perspectives on Outcome Domains of Medication Adherence Trials in Inflammatory Arthritis: An International OMERACT Focus Group Study. The Journal of Rheumatology 48:9, pages 1480-1487.
Crossref
Crossref
Alia Fazaa, Yasmine Makhlouf, Amad Ben Ouhiba, Saoussen Miladi, Mariem Sellami, Kmar Ouenniche, Leila Souabni, Salma Kassab, Selma Chekili, Leith Zakraoui, Kawther Ben Abdelghani & Ahmed Laatar. (2021) Adherence to biologic disease-modifying antirheumatic drugs in adult patients with rheumatic diseases. Therapies 76:5, pages 467-474.
Crossref
Crossref
Kostas Athanasakis, Michael Igoumenidis, Nadia Boubouchairopoulou, Elli Vitsou & John Kyriopoulos. (2021) Two Sides of the Same Coin? A Dual Multiple Criteria Decision Analysis of Novel Treatments Against Rheumatoid Arthritis in Physicians and Patients. Clinical Therapeutics 43:9, pages 1547-1557.
Crossref
Crossref
Filippo Fagni, Johannes Knitza, Martin Krusche, Arnd Kleyer, Koray Tascilar & David Simon. (2021) Digital Approaches for a Reliable Early Diagnosis of Psoriatic Arthritis. Frontiers in Medicine 8.
Crossref
Crossref
Katherine A. Kelly, Adaora Ewulu, Veronica K. Emmerich, Courtney E. Heron & Steven R. Feldman. (2021) Refractory Pediatric Psoriasis and Atopic Dermatitis: The Importance of Therapeutical Adherence and Biological Management. Biomedicines 9:8, pages 958.
Crossref
Crossref
A Mark FendrickDiana BrixnerDavid T RubinPhilip MeaseHarry LiuMatthew DavisManish Mittal. (2021) Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit. Journal of Managed Care & Specialty Pharmacy 27:8, pages 1086-1095.
Crossref
Crossref
Megan E PeterAutumn D ZuckermanJosh DeClercqLeena ChoiCameron JamesKatrina CooperJeannie ChoiMichael NadlerS Bobo Tanner. (2021) Adherence and persistence in patients with rheumatoid arthritis at an integrated health system specialty pharmacy. Journal of Managed Care & Specialty Pharmacy 27:7, pages 882-890.
Crossref
Crossref
Joshua Holmes & Liam G. Heaney. (2021) Measuring adherence to therapy in airways disease. Breathe 17:2, pages 210037.
Crossref
Crossref
A. Blauvelt, C. Leonardi, B. Elewski, J.J. Crowley, L.C. Guenther, M. Gooderham, R.G. Langley, R. Vender, A. Pinter, C.E.M. Griffiths, Y. Tada, H. Elmaraghy, R.G. Lima, G. Gallo, L. Renda, R. Burge, S.Y. Park, B. Zhu & K. Papp. (2020) A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial*. British Journal of Dermatology 184:6, pages 1047-1058.
Crossref
Crossref
Jordi Gratacós, Frank Behrens, Laura C. Coates, Ennio Lubrano, Diamant Thaçi, Christine Bundy, Jenny de la Torre-Aboki, Jesus Luelmo, Hanneke Voorneveld & Pascal Richette. (2021) A 12-point recommendation framework to support advancement of the multidisciplinary care of psoriatic arthritis: A call to action. Joint Bone Spine 88:3, pages 105175.
Crossref
Crossref
Susan Chang, Marilyn Stebbins, Edward A. Witt, Heather Kirkham, Troy Santos & Jennifer Cocohoba. (2021) Medication‐related problems in chronic inflammatory conditions: A pharmacy claims and electronic health record analysis. JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY 4:5, pages 570-579.
Crossref
Crossref
Benjamin Lockshin, Angel Cronin, Ryan W. Harrison, Robert R. McLean, Laura Anatale‐Tardiff, Russel Burge, Baojin Zhu, William N. Malatestinic, Bilal Atiya, Mwangi J. Murage, Gaia Gallo, Bruce Strober & Abby Van Voorhees. (2021) Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry. Dermatologic Therapy 34:2.
Crossref
Crossref
Jacob T. Maddux, Jonathan W. Inselman, Molly M. Jeffery, Regina W. Lam, Nilay D. Shah & Matthew A. Rank. (2021) Adherence to Asthma Biologics. Chest 159:3, pages 924-932.
Crossref
Crossref
Peter Hur, Nina Kim, Dong Dai, Olivia W. Piao, Josh Z. Zheng & Esther Yi. (2020) Healthcare Cost and Utilization Associated with Biologic Treatment Patterns Among Patients with Psoriatic Arthritis: Analyses from a Large US Claims Database. Drugs - Real World Outcomes 8:1, pages 29-38.
Crossref
Crossref
Philipp Sewerin, Kathrin Borchert, Dominic Meise, Matthias Schneider & Jörg Mahlich. (2021) Real-World Treatment Persistence with Biologic Disease-Modifying Antirheumatic Drugs Among German Patients with Psoriatic Arthritis—A Retrospective Database Study. Rheumatology and Therapy 8:1, pages 483-497.
Crossref
Crossref
Dimitrios A. Pappas, Taylor Blachley, Jennie H. Best, Steve Zlotnick, William G. Reiss, Kelechi Emeanuru & Joel M. Kremer. (2021) Durability of Response to Tocilizumab Therapy in Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry. Rheumatology and Therapy 8:1, pages 467-481.
Crossref
Crossref
Claire A. Butler & Liam G. Heaney. (2021) Fractional exhaled nitric oxide and asthma treatment adherence. Current Opinion in Allergy & Clinical Immunology 21:1, pages 59-64.
Crossref
Crossref
Viviana Marzaioli, Mary Canavan, Alex Donnelly, Siobhan Wade, Alexander Fraser, Tim O'Sullivan, Sinead Harney, Arthritis Ireland, Douglas J. Veale & Ursula Fearon. (2023) Knowledge of disease, diagnosis, adherence and impact of research in an Irish cohort of patients with inflammatory arthritis. HRB Open Research 4, pages 60.
Crossref
Crossref
Jonathan I. Silverberg, Emma Guttman-Yassky, Abhijit Gadkari, Andreas Kuznik, Usha G. Mallya, Vera Mastey, Haixin Zhang, Zhen Chen, Cheng Chen, Andrew Korotzer, Debra Sierka, Miriam C. Fenton, Mandeep Kaur & Jessica J. Jalbert. (2021) Real-world persistence with dupilumab among adults with atopic dermatitis. Annals of Allergy, Asthma & Immunology 126:1, pages 40-45.
Crossref
Crossref
Stanley B. Cohen, Jeffrey D. Greenberg, James Harnett, Ann Madsen, Timothy W. Smith, David Gruben, Richard Zhang, Tatjana Lukic, John Woolcott, Kimberly J. Dandreo, Heather J. Litman, Taylor Blachley, Anne Lenihan, Connie Chen, Jose L. Rivas & Maxime Dougados. (2020) Real-World Evidence to Contextualize Clinical Trial Results and Inform Regulatory Decisions: Tofacitinib Modified-Release Once-Daily vs Immediate-Release Twice-Daily for Rheumatoid Arthritis. Advances in Therapy 38:1, pages 226-248.
Crossref
Crossref
Luca Navarini, Luisa Costa, Marco Tasso, Maria Sole Chimenti, Damiano Currado, Giulia Lavinia Fonti, Massimo Ciccozzi, Domenico Paolo Emanuele Margiotta, Carolina Benigno, Erica De Martino, Roberto Perricone, Antonella Afeltra, Raffaele Scarpa & Francesco Caso. (2020) Retention rates and identification of factors associated with anti-TNFα, anti-IL17, and anti-IL12/23R agents discontinuation in psoriatic arthritis patients: results from a real-world clinical setting. Clinical Rheumatology 39:9, pages 2663-2670.
Crossref
Crossref
Kirk Geale, Ingrid Lindberg, Emma C Paulsson, E Christina M Wennerström, Anna Tjärnlund, Wim Noel, Dana Enkusson & Elke Theander. (2020) Persistence of biologic treatments in psoriatic arthritis: a population-based study in Sweden. Rheumatology Advances in Practice 4:2.
Crossref
Crossref
Liz Van Rossen, Antoni Chan, Annie Gilbert, Karl Gaffney, Claire Harris, Pedro M Machado, Liliana R Santos, Raj Sengupta, Paul Basset & Andrew Keat. (2020) Response to lower dose TNF inhibitors in axial spondyloarthritis; a real-world multicentre observational study. Rheumatology Advances in Practice 4:2.
Crossref
Crossref
A. Blauvelt, K. Papp, A. GottliebA. JarellK. Reich, C. Maari, K.B. GordonL.K. FerrisR.G. Langley, Y. Tada, R.G. LimaH. ElmaraghyG. GalloL. RendaS.Y. ParkR. BurgeJ. BagelRonald Vender, Mark A. Lomaga, Isabelle Delorme, Chih‐Ho Hong, Richard L. Langley, Lorne Albrecht, Lyn Guenther, Catherine Maari, Kim Papp, Kamal K. Singh Ohson, Kirk Barber, Charles Lynde, Aditya Gupta, Leslie Rosoph, Jean‐Sébastien Gauthier, Melinda Gooderham, Norman Wasel, Mani Raman, Marni Wiseman, David Greenstein, Abel Jarell, Charles Moon, Lani Clark, Sadra Sasha Jazayeri, Michael Bukhalo, Angela Moore, Tiffani K. Hamilton, Aron Gewirtzman, Lydie Hazan, Jeffrey Crowley, Craig Teller, Matthew Zirwas, Stacy R. Smith, M. Christine Lee, Stephen Tyring, Patricia Lee, Sunil Dhawan, Craig Leonardi, Amarilis Perez‐De Jesus, Wendy McFalda, Ellen Frankel, Paul Yamauchi, Scott Fretzin, Rocco Serrao, Todd Schlesinger, Scott Gottlieb, Peter Jenkin, Rola Gharib, Steven Davis, Navid Nami, Zoe Diana Draelos, Lloyd Godwin, Cindy Owen, Megan Landis, William Abramovits, Samuel Sanchez‐Rivera, Abby Van Voorhees, David Fivenson, Francisco Kerdel, Seth B. Forman, Jeffrey Weinberg, Jose Gonzalez‐Chavez, Brent Boyce, Linda Stein‐Gold, Charles Hudson, Constance Brown, James Coggi, Christina Feser, Rion Forconi, Sandra Johnson, Mark McCune, Lawrence Green, Vandana Madkan, Dana Maxwell Shipp, Kenneth Gordon, Jill Waibel, Oscar Soto‐Raices, Jennifer Cather, Scott Miller, John Scott, Douglas Young, Jessica Kaffenberger, Kelley Yokum, Matthew Zook, Andrew Blauvelt, Artis Truett, George Schmieder, Gary McCracken, Patrick McElgunn, James Herrmann, Jeffery M. Suchniak, James Appel, Elizabeth Barranco, Mark Lee, Jerry Bagel, Lawrence Osman, Ashley Cauthen, Neil Sadick, Eneida De La Torre, Kelly Taylor, David Cohen, Holly Hake Harris, Jennifer Soung, Vassilios Dimitropoulos, Stephen Miller, Cathy Barnes, Rawan Jumean‐Haddad, Suzanne Bruce, Lawrence Cheung, Scott Guenthner, Anthony Gaspari, Vivian Laquer, James M. Krell, Shahram Jacobs, Walter Nahm, Neil Korman, Boni Elewski, Laura Ferris, Kristina Callis Duffin, David Pariser, Brian Johnson, Paul Wallace, Jeffrey Travers & Richard Fried. (2020) A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial. British Journal of Dermatology 182:6, pages 1348-1358.
Crossref
Crossref
Jennie H. Best, Steven C. Vlad, Lenore Tominna & Ibrahim Abbass. (2020) Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic. Rheumatology and Therapy 7:2, pages 345-355.
Crossref
Crossref
Andrew Blauvelt, Nianwen Shi, Russel Burge, William N. Malatestinic, Chen-Yen Lin, Carolyn R. Lew, Nicole M. Zimmerman, Orin M. Goldblum, Baojin Zhu & Mwangi J. Murage. (2020) Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab. Journal of the American Academy of Dermatology 82:4, pages 927-935.
Crossref
Crossref
M. Rijsbergen, T. Niemeyer‐van der Kolk, R. Rijneveld, J.H.F.M. Pinckaers, I. Meshcheriakov, J.N. Bouwes Bavinck, M.B.A. van Doorn, G. Hogendoorn, G. Feiss, A.F. Cohen, J. Burggraaf, M.I.E. van Poelgeest & R. Rissmann. (2019) Mobile e‐diary application facilitates the monitoring of patient‐reported outcomes and a high treatment adherence for clinical trials in dermatology. Journal of the European Academy of Dermatology and Venereology 34:3, pages 633-639.
Crossref
Crossref
Clélia Monchablon, Henri Gondé, Sophie Pouplin, Rémi Varin, Olivier Vittecoq & Thierry Lequerré. (2019) Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis. Clinical Rheumatology 39:1, pages 207-216.
Crossref
Crossref
Mélanie Sustersic, Aurélie Gauchet, Amélie Duvert, Laure Gonnet, Alison Foote, Céline Vermorel, Benoit Allenet & Jean-Luc Bosson. (2019) Proposal for a Global Adherence Scale for Acute Conditions (GASAC): A prospective cohort study in two emergency departments. PLOS ONE 14:12, pages e0215415.
Crossref
Crossref
A. M. Lila, R. O. Dreval, O. V. Inamova, V. V. Shipitsyn & A. N. Zabotina. (2019) Medical and economic analysis of the impact of rheumatoid disease-associated disability on the country's economy in terms of implementation of pension reforms. Modern Rheumatology Journal 13:4, pages 18-25.
Crossref
Crossref
Karin Luttropp, Mary Dozier, Nahila Justo, Freddy Cornillie, Sumesh Kachroo, Marinella Govoni, Stina Salomonsson, Christopher M Black & Ahmed Khalifa. (2019) Real-world treatment persistence of golimumab in the management of immune-mediated rheumatic diseases in Europe: a systematic literature review. BMJ Open 9:5, pages e027456.
Crossref
Crossref